Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients
Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients
复制标题
DOI：
10.1373/49.3.450
复制
发表时间：
2003-03-01
影响因子：
9.3
通讯作者：
Jeffrey, G
中科院分区：
文献类型：
--
作者：
Rossi, E;Adams, L;Jeffrey, G
背景：通过肝活检确定肝纤维化的分期对治疗丙型肝炎病毒感染的患者很重要。我们研究了专有FibroTest评分的预测价值，以准确地识别澳大利亚丙型肝炎patients.Methods显著纤维化：从125例确诊的丙型肝炎患者抗病毒治疗前的血清中获得的结合珠蛋白，α（2）-巨球蛋白，载脂蛋白A1，胆红素和γ-谷氨酰转移酶活性进行了分析，并计算FibroTest评分。肝纤维化病理根据定义的系统在F0至F4的量表上进行分期。我们使用预测值和ROC曲线来评估FibroTest scores.Results的准确性：肝活检定义的显著纤维化的患病率为0.38。预测显著纤维化最有用的单一检测是血清α 2-巨球蛋白（临界值，2.52 g/L;敏感性，75%;特异性，67%）。FibroTest评分0.6的阴性预测值为78%。虽然125名患者中有33名FibroTest评分0.6，可能有显著的纤维化，但5名（21%）有轻度纤维化。在队列中的125例患者中，57例（46%）可以避免肝活检，但在这57例患者中有11例（19%）记录了不一致的结果。结论：FibroTest评分不能准确预测是否存在显著的肝纤维化。(C)2003年美国临床化学协会。
Background: Determining the stage of fibrosis by liver biopsy is important in managing patients with hepatitis C virus infection. We investigated the predictive value of the proprietary FibroTest score to accurately identify significant fibrosis in Australian hepatitis C patients.Methods: Serum obtained from 125 confirmed hepatitis C patients before antiviral therapy was analyzed for haptoglobin, alpha(2)-macroglobulin, apolipoprotein A1, bilirubin, and gamma-glutamyltransferase activity, and the FibroTest score was computed. Liver fibrosis pathology was staged according to a defined system on a scale of FO to F4. We used predictive values and a ROC curve to assess the accuracy of FibroTest scores.Results: The prevalence of significant fibrosis defined by liver biopsy was 0.38. The most useful single test for predicting significant fibrosis was serum alpha(2)-macroglobulin (cutoff value, 2.52 g/L; sensitivity, 75%; specificity, 67%). The negative predictive value of a FibroTest score 0.6 was 78%. Although 33 of the 125 patients had FibroTest scores 0.6 who were likely to have significant fibrosis, 5 (21%) had mild fibrosis. Of the 125 patients in the cohort, 57 (46%) could have avoided liver biopsy, but discrepant results were recorded in 11 of those 57 (19%).Conclusion: The FibroTest score could not accurately predict the presence or absence of significant liver fibrosis. (C) 2003 American Association for Clinical Chemistry.